Kyowa Kirin.
pharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 52
What's happening
Earlier this month
One to three months ago
-
Kyowa Kirin, Eli Lilly, Kura Oncology, and others are forming a new company to focus on menin inhibitors for disease, involving investment and shared operational teams.Some support1 report
-
Kyowa Kirin conducts business in the Americas, US, and Japan markets.Some support1 report
-
Manufacturers committed to a $19.6B US manufacturing investment and contributing APIs to national reserves.Some support2 reports
-
Kyowa Kirin, headquartered in Tokyo, is building a new life sciences facility in Sanford, North Carolina.Some support4 reports1 development inside
-
Kyowa Kirin committed to investing in a life sciences facility in Lee County, North Carolina, partnering with Central Carolina Community College and Pfizer.Some support1 report
-
Benchling and Kyowa Kirin are implementing an AI platform for centralized data management and R&D research in Japan.Some support1 report
-
Kura Oncology reported its earnings on Nasdaq on August 12, 2026. Kyowa Kirin announced it was funding Kura's program.Some support4 reports
Gone quiet
No new reports in 90+ days-
FDA granted Breakthrough Therapy Designation to Ziftomenib and entered a global strategic collaboration agreement.Some support4 reports1 development inside
-
The FDA has selected a facility for a PreCheck Pilot Program involving Kyowa Kirin.Some support1 report
-
Angela Williams is the Global Head of Health Economics at Kyowa Kirin, and H. Miles Prince is a Principal Investigator at the Peter MacCallum Cancer Centre.Some support1 report
-
The Cutaneous Lymphoma Foundation collaborated with Kyowa Kirin on studies, presenting data at a Congress in Montreal.Some support1 report
-
Kyowa Kirin and Otsuka Holdings Co., Ltd., two medical companies, are currently competing for investment.Some support2 reports
-
Ardelyx has received FDA-approved treatments and strengthened its global reach through a partnership.Well supported6 reports1 development inside
No events began in the chosen period. Widen it, or reset.
Around Kyowa Kirin this week
News at the entities that move Kyowa Kirin most-
Donald Trump OperationalTrump allegedly ignored Graham's sanctions bill, slowed Starlink connections, and lifted sanctions to help Putin.Moves Kyowa Kirin
-
FDA StructuralNeurogene Inc. developed a gene therapy for Rett syndrome and received FDA agreement for a registrational trial design.Moves Kyowa Kirin
-
Jefferies Financial Group Mentioned togetherGE Vernova received a 'buy' rating and target price raise from Jefferies, alongside required SEC filings on May 27, 2026.Moves Kyowa Kirin
-
Amgen OperationalLaurus Labs is shifting focus from building to filling capacity and may participate in Amgen's supply chain.Moves Kyowa Kirin
-
Sanford StructuralPaul Williams represented Sanford Main Street on October 19, 2026.Moves Kyowa Kirin
-
Central Carolina Community College StructuralCaterpillar is partnering with Central Carolina Community College to invest in workforce development in Sanford, North Carolina.Moves Kyowa Kirin
Connections
The 23 strongest of 52, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Kura Oncology Operational
Kura Oncology and Kyowa Kirin maintain a strategic collaboration for joint development and commercialization of ziftomenib.
-
Angela Williams Structural
Angela Williams serves as the Global Head Health Economics at Kyowa Kirin.
-
Benchling Structural
Benchling provides centralized data management and discovery services utilized by Kyowa Kirin.
-
Sanford Structural
Kyowa Kirin is establishing a biomanufacturing facility in Sanford, creating a structural dependency.
-
Donald Trump Operational
Trump's drug plan and associated deals explicitly include Kyowa Kirin as a participant in policy initiatives.
-
Fosun Pharmaceutical Structural
The companies are formally partnered with Ardelyx for therapeutics development.
-
Central Carolina Community College Structural
Kyowa Kirin provides ongoing facility and hub support for Central Carolina Community College.
-
FDA Structural
Kyowa Kirin's U.S. manufacturing establishment is subject to FDA regulatory oversight.
Show all 23 connections
-
Amgen Operational
Amgen and Kyowa Kirin are engaged in a functional partnership regarding Amgen's product portfolio.
-
Astellas Pharma Operational
Both companies are active participants in the same market pricing program and US manufacturing investment initiatives.
-
Cutaneous Lymphoma Foundation Operational
The Foundation engages in active research partnerships with the pharmaceutical company on medical studies.
-
Berlin Mentioned together
Kyowa Kirin was involved in a findings presentation held in Berlin.
-
Tokyo Shared context
Kyowa Kirin is a company that operates from its headquarters located in the city of Tokyo.
-
North Carolina Shared context
Kyowa Kirin operates from a facility situated within North Carolina's life sciences sector.
-
Julia Scarisbrick Operational
Julia Scarisbrick provides support and validation for study findings published by Kyowa Kirin.
-
Princeton Shared context
Kyowa Kirin operates from a location within Princeton, New Jersey.
-
Lee County Transactional
Kyowa Kirin committed to investing in Lee County.
-
Montreal Shared context
The relationship is defined by the location where a study presentation took place.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provided a stock rating downgrade for Kyowa Kirin.
-
Steris Shared context
Both companies are noted as operating within the same life sciences industry hub.
-
Americas Shared context
Kyowa Kirin conducts business operations within the Americas market.
-
La Jolla Shared context
Kyowa Kirin maintains a research facility within the geographic area of La Jolla, CA.
-
Knight Therapeutics Mentioned together
No direct relationship between Knight Therapeutics and Kyowa Kirin was observed in the provided evidence.
History
Events by the month they beganOctober 2026
1 eventSeptember 2026
3 events- Jefferies lowered Kyowa Kirin's stock rating on September 1, 2026, for the company headquartered in Tokyo.
- Kyowa Kirin, Eli Lilly, Kura Oncology, and others are forming a new company to focus on menin inhibitors for disease, involving investment and shared operational teams.
- Kyowa Kirin conducts business in the Americas, US, and Japan markets.
August 2026
4 events- Manufacturers committed to a $19.6B US manufacturing investment and contributing APIs to national reserves.
- Kyowa Kirin committed to investing in a life sciences facility in Lee County, North Carolina, partnering with Central Carolina Community College and Pfizer.
- Benchling and Kyowa Kirin are implementing an AI platform for centralized data management and R&D research in Japan.
- Kura Oncology reported its earnings on Nasdaq on August 12, 2026. Kyowa Kirin announced it was funding Kura's program.
Show 1 earlier month
June 2026
7 events- Kyowa Kirin, headquartered in Tokyo, is building a new life sciences facility in Sanford, North Carolina.
- FDA granted Breakthrough Therapy Designation to Ziftomenib and entered a global strategic collaboration agreement.
- The FDA has selected a facility for a PreCheck Pilot Program involving Kyowa Kirin.
- Angela Williams is the Global Head of Health Economics at Kyowa Kirin, and H. Miles Prince is a Principal Investigator at the Peter MacCallum Cancer Centre.
- The Cutaneous Lymphoma Foundation collaborated with Kyowa Kirin on studies, presenting data at a Congress in Montreal.
- Kyowa Kirin and Otsuka Holdings Co., Ltd., two medical companies, are currently competing for investment.
- Ardelyx has received FDA-approved treatments and strengthened its global reach through a partnership.